Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen J Forman

Showing results (371-380 of 504) with videos related to

Pageof 51
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2024
Sex-Based Differences in Risk of Therapy-Related Myeloid NeoplasmsMelissa A Richard, Chengcheng Yan, Yanjun Chen, et al.
Leukemia Research|June 9, 2012
Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxisRyotaro Nakamura, Joycelynne M Palmer, Margaret R O'Donnell, et al.
Bone Marrow Transplantation|June 10, 2021
Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantationStephanie Mac, Dat Ngo, Dongyun Yang, et al.
Blood Advances|July 15, 2022
Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamideMonzr M Al Malki, Joycelynne Palmer, Ni-Chun Tsai, et al.
Journal of the National Cancer Institute|July 10, 2025
Clonal hematopoiesis and risk of non-myeloid subsequent malignant neoplasms after autologous hematopoietic cell transplantationJune-Wha Rhee, Sitong Chen, Raju Pillai, et al.
Blood Advances|January 10, 2022
Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunityHoda Pourhassan, Corinna La Rosa, Flavia Chiuppesi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 30, 2003
Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplantLyle C Feinstein, Brenda M Sandmaier, David G Maloney, et al.
Blood Advances|January 10, 2019
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimenHaris Ali, Ibrahim Aldoss, Dongyun Yang, et al.
American Journal of Hematology|March 18, 2026
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell LymphomaGeoffrey Shouse, Matthew Matasar, Lu Chen, et al.
Cancer Discovery|April 10, 2021
IFNγ Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous ImmunityDarya Alizadeh, Robyn A Wong, Sharareh Gholamin, et al.
Pageof 51

Showing results (371-380 of 504) with videos related to

Sort By:
Pageof 51
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2024
Sex-Based Differences in Risk of Therapy-Related Myeloid NeoplasmsMelissa A Richard, Chengcheng Yan, Yanjun Chen, et al.
Leukemia Research|June 9, 2012
Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxisRyotaro Nakamura, Joycelynne M Palmer, Margaret R O'Donnell, et al.
Bone Marrow Transplantation|June 10, 2021
Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantationStephanie Mac, Dat Ngo, Dongyun Yang, et al.
Blood Advances|July 15, 2022
Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamideMonzr M Al Malki, Joycelynne Palmer, Ni-Chun Tsai, et al.
Journal of the National Cancer Institute|July 10, 2025
Clonal hematopoiesis and risk of non-myeloid subsequent malignant neoplasms after autologous hematopoietic cell transplantationJune-Wha Rhee, Sitong Chen, Raju Pillai, et al.
Blood Advances|January 10, 2022
Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunityHoda Pourhassan, Corinna La Rosa, Flavia Chiuppesi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 30, 2003
Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplantLyle C Feinstein, Brenda M Sandmaier, David G Maloney, et al.
Blood Advances|January 10, 2019
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimenHaris Ali, Ibrahim Aldoss, Dongyun Yang, et al.
American Journal of Hematology|March 18, 2026
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell LymphomaGeoffrey Shouse, Matthew Matasar, Lu Chen, et al.
Cancer Discovery|April 10, 2021
IFNγ Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous ImmunityDarya Alizadeh, Robyn A Wong, Sharareh Gholamin, et al.
Pageof 51